Pre-close period Trading Upda
Issued by Citigate Dewe Rogerson Ltd, Birmingham
Date: Tuesday, 12 January 2010
Dechra® Pharmaceuticals PLC
("Dechra" or "The Group")
Pre-close period Trading Update
The Board of Dechra issues the following trading update ahead of the publication of the Group's Half-Year Results for the six months ended 31 December 2009 which are scheduled to be announced on Tuesday 23 February 2010.
Trading Update
Group revenue for the six months ended 31 December 2009 was approximately 6.5% ahead of the equivalent period last year.
Pharmaceuticals Division
Overall revenue from this division was approximately 12.6% higher than the equivalent period in 2008.
Our lead pharmaceutical product, Vetoryl®, continued to show good growth in all markets including sales for the six months of $2.5 million in the USA, where over 25% of companion animal practices (approximately 7,000) have now purchased the product.
Our diets range, branded Specific®, showed solid growth across Europe.
Dales Pharmaceuticals, our manufacturing business, made good progress in the period increasing its revenue from third party customers.
Services Division
Revenue from this division for the six months ended 31 December 2009 was 4.6% up on the equivalent period in the prior year with the growth rate being higher in the second quarter than the first quarter. Effective cost control at our distribution business, NVS®, ensured that the operating margin has continued to be maintained at the level achieved for the year ended 30 June 2009.
Summary
Trading in the first half of the financial year has been in line with management's expectations. Despite continuing economic uncertainty, there are indications of volume growth starting to return to the market. This growth, together with the continued penetration of our own branded products, impending new product launches in the EU and a robust development pipeline, enables the Board to look to the future with optimism.
|
Enquiries: |
|
|
Ian Page, Chief Executive |
Fiona Tooley, Director |
|
Simon Evans, Group Finance Director |
Keith Gabriel, Senior Account Manager |
|
Dechra Pharmaceuticals PLC |
Citigate Dewe Rogerson |
|
Telephone: + 44 (0) 1782 771100 |
Telephone: +44 (0) 121 362 4035 |
|
Mobile: +44 (0) 777 564 2222 (IP) |
Mobile: +44 (0) 778 570 3523 (FT) |
|
Mobile: +44 (0) 777 564 2220 (SE) |
Mobile: +44 (0) 777 078 8624 (KG) |
corporate.enquiries@dechra.com
Ticker: Sector: Full Listing (Pharmaceuticals): DPH
Trademarks appear throughout this release in italics. Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS
Latest directors dealings
- 6 hours ago Luceco
- 6 hours ago Helios Towers
- 7 hours ago Wise Class A
- 7 hours ago EDX Medical Group Plc
- 7 hours ago Naked Wines